• Something wrong with this record ?

Type I interferon signaling in malignant blasts contributes to treatment efficacy in AML patients

P. Holicek, I. Truxova, J. Rakova, C. Salek, M. Hensler, M. Kovar, M. Reinis, R. Mikyskova, J. Pasulka, S. Vosahlikova, H. Remesova, I. Valentova, D. Lysak, M. Holubova, P. Kaspar, J. Prochazka, L. Kasikova, R. Spisek, L. Galluzzi, J. Fucikova

. 2023 ; 14 (3) : 209. [pub] 20230324

Language English Country England, Great Britain

Document type Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.

Persistent link   https://www.medvik.cz/link/bmc23003752

Grant support
U54 CA274291 NCI NIH HHS - United States

While type I interferon (IFN) is best known for its key role against viral infection, accumulating preclinical and clinical data indicate that robust type I IFN production in the tumor microenvironment promotes cancer immunosurveillance and contributes to the efficacy of various antineoplastic agents, notably immunogenic cell death inducers. Here, we report that malignant blasts from patients with acute myeloid leukemia (AML) release type I IFN via a Toll-like receptor 3 (TLR3)-dependent mechanism that is not driven by treatment. While in these patients the ability of type I IFN to stimulate anticancer immune responses was abolished by immunosuppressive mechanisms elicited by malignant blasts, type I IFN turned out to exert direct cytostatic, cytotoxic and chemosensitizing activity in primary AML blasts, leukemic stem cells from AML patients and AML xenograft models. Finally, a genetic signature of type I IFN signaling was found to have independent prognostic value on relapse-free survival and overall survival in a cohort of 132 AML patients. These findings delineate a clinically relevant, therapeutically actionable and prognostically informative mechanism through which type I IFN mediates beneficial effects in patients with AML.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23003752
003      
CZ-PrNML
005      
20230425140851.0
007      
ta
008      
230418s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41419-023-05728-w $2 doi
035    __
$a (PubMed)36964168
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Holicek, Peter $u Sotio Biotech, Prague, Czech Republic $u Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic $1 https://orcid.org/0000000202684915
245    10
$a Type I interferon signaling in malignant blasts contributes to treatment efficacy in AML patients / $c P. Holicek, I. Truxova, J. Rakova, C. Salek, M. Hensler, M. Kovar, M. Reinis, R. Mikyskova, J. Pasulka, S. Vosahlikova, H. Remesova, I. Valentova, D. Lysak, M. Holubova, P. Kaspar, J. Prochazka, L. Kasikova, R. Spisek, L. Galluzzi, J. Fucikova
520    9_
$a While type I interferon (IFN) is best known for its key role against viral infection, accumulating preclinical and clinical data indicate that robust type I IFN production in the tumor microenvironment promotes cancer immunosurveillance and contributes to the efficacy of various antineoplastic agents, notably immunogenic cell death inducers. Here, we report that malignant blasts from patients with acute myeloid leukemia (AML) release type I IFN via a Toll-like receptor 3 (TLR3)-dependent mechanism that is not driven by treatment. While in these patients the ability of type I IFN to stimulate anticancer immune responses was abolished by immunosuppressive mechanisms elicited by malignant blasts, type I IFN turned out to exert direct cytostatic, cytotoxic and chemosensitizing activity in primary AML blasts, leukemic stem cells from AML patients and AML xenograft models. Finally, a genetic signature of type I IFN signaling was found to have independent prognostic value on relapse-free survival and overall survival in a cohort of 132 AML patients. These findings delineate a clinically relevant, therapeutically actionable and prognostically informative mechanism through which type I IFN mediates beneficial effects in patients with AML.
650    _2
$a lidé $7 D006801
650    12
$a akutní myeloidní leukemie $x patologie $7 D015470
650    12
$a protinádorové látky $x terapeutické užití $7 D000970
650    _2
$a výsledek terapie $7 D016896
650    _2
$a signální transdukce $7 D015398
650    12
$a interferon typ I $7 D007370
650    _2
$a nádorové mikroprostředí $7 D059016
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a Research Support, U.S. Gov't, Non-P.H.S. $7 D013486
700    1_
$a Truxova, Iva $u Sotio Biotech, Prague, Czech Republic
700    1_
$a Rakova, Jana $u Sotio Biotech, Prague, Czech Republic
700    1_
$a Salek, Cyril $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic $u Institute of Clinical and Experimental Hematology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Hensler, Michal $u Sotio Biotech, Prague, Czech Republic
700    1_
$a Kovar, Marek $u Laboratory of Tumor Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Reinis, Milan $u Laboratory of Immunological and Tumour Models, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Mikyskova, Romana $u Laboratory of Immunological and Tumour Models, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Pasulka, Josef $u Sotio Biotech, Prague, Czech Republic
700    1_
$a Vosahlikova, Sarka $u Sotio Biotech, Prague, Czech Republic
700    1_
$a Remesova, Hana $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Valentova, Iva $u Sotio Biotech, Prague, Czech Republic $u Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic
700    1_
$a Lysak, Daniel $u Department of Hematology and Oncology, Faculty Hospital in Pilsen, Pilsen, Czech Republic
700    1_
$a Holubova, Monika $u Biomedical Center, Medical Faculty in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Kaspar, Petr $u Czech Centre for Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Prochazka, Jan $u Czech Centre for Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Kasikova, Lenka $u Sotio Biotech, Prague, Czech Republic
700    1_
$a Spisek, Radek $u Sotio Biotech, Prague, Czech Republic $u Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic
700    1_
$a Galluzzi, Lorenzo $u Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA. deadoc80@gmail.com $u Sandra and Edward Meyer Cancer Center, New York, NY, USA. deadoc80@gmail.com $u Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA. deadoc80@gmail.com $1 https://orcid.org/0000000322578500
700    1_
$a Fucikova, Jitka $u Sotio Biotech, Prague, Czech Republic. fucikova@sotio.com $u Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic. fucikova@sotio.com $1 https://orcid.org/000000028423479X $7 xx0116819
773    0_
$w MED00173233 $t Cell death & disease $x 2041-4889 $g Roč. 14, č. 3 (2023), s. 209
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36964168 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425140848 $b ABA008
999    __
$a ok $b bmc $g 1924434 $s 1189961
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 14 $c 3 $d 209 $e 20230324 $i 2041-4889 $m Cell death & disease $n Cell Death Dis $x MED00173233
GRA    __
$a U54 CA274291 $p NCI NIH HHS $2 United States
LZP    __
$a Pubmed-20230418

Find record

Citation metrics

Archiving options